International Journal of Cancer Management

Published by: Kowsar

Plasma Cell Immunophenotyping Improve Prognostic Stratification of Multiple Myeloma Patients

Yanis Meddour 1 , * , Momahed Cherif Rahali 2 , Salah Eddine Belakehal 2 , Nacera Benfenatki 3 , Fatma Zohra Ardjoune 2 , Samia Chaib 1 and Reda Djidjik 4
Authors Information
1 Immunology Department, Central Hospital of Army, Algiers, Algeria
2 Hematology Department, Central Hospital of Army, Algiers, Algeria
3 Internal Medicine Department, EPH Rouiba, Algiers, Algeria
4 Immunology Department, Beni-Messous University Hospital, Algiers, Algeria
Article information
  • International Journal of Cancer Management: January 2018, 11 (1); e5350
  • Published Online: January 23, 2018
  • Article Type: Research Article
  • Received: January 10, 2016
  • Revised: October 23, 2017
  • Accepted: January 17, 2018
  • DOI: 10.5812/ijcm.5350

To Cite: Meddour Y, Cherif Rahali M, Eddine Belakehal S, Benfenatki N, Zohra Ardjoune F, et al. Plasma Cell Immunophenotyping Improve Prognostic Stratification of Multiple Myeloma Patients, Int J Cancer Manag. 2018 ; 11(1):e5350. doi: 10.5812/ijcm.5350.

Copyright © 2018, Cancer Research Center (CRC), Shahid Beheshti University of Medical Sciences. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License ( which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited
1. Background
2. Methods
3. Results
4. Discussion
  • 1. Kumar S, Kimlinger T, Morice W. Immunophenotyping in multiple myeloma and related plasma cell disorders. Best Pract Res Clin Haematol. 2010;23(3):433-51. doi: 10.1016/j.beha.2010.09.002. [PubMed: 21112041].
  • 2. Paiva B, Almeida J, Perez-Andres M, Mateo G, Lopez A, Rasillo A, et al. Utility of flow cytometry immunophenotyping in multiple myeloma and other clonal plasma cell-related disorders. Cytometry B Clin Cytom. 2010;78(4):239-52. doi: 10.1002/cyto.b.20512. [PubMed: 20155853].
  • 3. Raja KR, Kovarova L, Hajek R. Review of phenotypic markers used in flow cytometric analysis of MGUS and MM, and applicability of flow cytometry in other plasma cell disorders. Br J Haematol. 2010;149(3):334-51. doi: 10.1111/j.1365-2141.2010.08121.x. [PubMed: 20201947].
  • 4. San Miguel JF, Almeida J, Mateo G, Blade J, Lopez-Berges C, Caballero D, et al. Immunophenotypic evaluation of the plasma cell compartment in multiple myeloma: a tool for comparing the efficacy of different treatment strategies and predicting outcome. Blood. 2002;99(5):1853-6. doi: 10.1182/blood.V99.5.1853. [PubMed: 11861305].
  • 5. Lin P, Owens R, Tricot G, Wilson CS. Flow cytometric immunophenotypic analysis of 306 cases of multiple myeloma. Am J Clin Pathol. 2004;121(4):482-8. doi: 10.1309/74R4-TB90-BUWH-27JX. [PubMed: 15080299].
  • 6. Perez-Persona E, Vidriales MB, Mateo G, Garcia-Sanz R, Mateos MV, de Coca AG, et al. New criteria to identify risk of progression in monoclonal gammopathy of uncertain significance and smoldering multiple myeloma based on multiparameter flow cytometry analysis of bone marrow plasma cells. Blood. 2007;110(7):2586-92. doi: 10.1182/blood-2007-05-088443. [PubMed: 17576818].
  • 7. Paiva B, Vidriales MB, Rosinol L, Martinez-Lopez J, Mateos MV, Ocio EM, et al. A multiparameter flow cytometry immunophenotypic algorithm for the identification of newly diagnosed symptomatic myeloma with an MGUS-like signature and long-term disease control. Leukemia. 2013;27(10):2056-61. doi: 10.1038/leu.2013.166. [PubMed: 23743858].
  • 8. Paiva B, Vidriales MB, Cervero J, Mateo G, Perez JJ, Montalban MA, et al. Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation. Blood. 2008;112(10):4017-23. doi: 10.1182/blood-2008-05-159624. [PubMed: 18669875].
  • 9. Perez-Persona E, Mateo G, Garcia-Sanz R, Mateos MV, de Las Heras N, de Coca AG, et al. Risk of progression in smouldering myeloma and monoclonal gammopathies of unknown significance: comparative analysis of the evolution of monoclonal component and multiparameter flow cytometry of bone marrow plasma cells. Br J Haematol. 2010;148(1):110-4. doi: 10.1111/j.1365-2141.2009.07929.x. [PubMed: 19821821].
  • 10. Paiva B, Vidriales MB, Mateo G, Perez JJ, Montalban MA, Sureda A, et al. The persistence of immunophenotypically normal residual bone marrow plasma cells at diagnosis identifies a good prognostic subgroup of symptomatic multiple myeloma patients. Blood. 2009;114(20):4369-72. doi: 10.1182/blood-2009-05-221689. [PubMed: 19755674].
  • 11. Mateo G, Montalban MA, Vidriales MB, Lahuerta JJ, Mateos MV, Gutierrez N, et al. Prognostic value of immunophenotyping in multiple myeloma: a study by the PETHEMA/GEM cooperative study groups on patients uniformly treated with high-dose therapy. J Clin Oncol. 2008;26(16):2737-44. doi: 10.1200/JCO.2007.15.4120. [PubMed: 18443352].
  • 12. San Miguel JF, Gutierrez NC, Mateo G, Orfao A. Conventional diagnostics in multiple myeloma. Eur J Cancer. 2006;42(11):1510-9. doi: 10.1016/j.ejca.2005.11.039. [PubMed: 16762540].
  • 13. Olteanu H, Wang HY, Chen W, McKenna RW, Karandikar NJ. Immunophenotypic studies of monoclonal gammopathy of undetermined significance. BMC Clin Pathol. 2008;8:13. doi: 10.1186/1472-6890-8-13. [PubMed: 19040735].
  • 14. Kraj M, Kopec-Szlezak J, Poglod R, Kruk B. Flow cytometric immunophenotypic characteristics of plasma cell leukemia. Folia Histochem Cytobiol. 2011;49(1):168-82. [PubMed: 21526505].
  • 15. Gupta R, Bhaskar A, Kumar L, Sharma A, Jain P. Flow cytometric immunophenotyping and minimal residual disease analysis in multiple myeloma. Am J Clin Pathol. 2009;132(5):728-32. doi: 10.1309/AJCP1GYI7EHQYUYK. [PubMed: 19846814].
  • 16. Klabusay M, Doubek M, Adam Z, Hajek R, Krivanova A. [Detection of myeloma cells in peripheral blood using multi-parameter flow cytometry: monitoring residual disease]. Cas Lek Cesk. 2000;139(14):432-6. [PubMed: 11048405].
  • 17. Paiva B, Vidriales MB, Perez JJ, Mateo G, Montalban MA, Mateos MV, et al. Multiparameter flow cytometry quantification of bone marrow plasma cells at diagnosis provides more prognostic information than morphological assessment in myeloma patients. Haematologica. 2009;94(11):1599-602. doi: 10.3324/haematol.2009.009100. [PubMed: 19880781].
  • 18. Kyle RA, Rajkumar SV. Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma. Leukemia. 2009;23(1):3-9. doi: 10.1038/leu.2008.291. [PubMed: 18971951].
  • 19. Kovarova L, Buresova I, Buchler T, Suska R, Pour L, Zahradova L, et al. Phenotype of plasma cells in multiple myeloma and monoclonal gammopathy of undetermined significance. Neoplasma. 2009;56(6):526-32. doi: 10.4149/neo_2009_06_526. [PubMed: 19728762].
  • 20. Sezer O, Heider U, Zavrski I, Possinger K. Differentiation of monoclonal gammopathy of undetermined significance and multiple myeloma using flow cytometric characteristics of plasma cells. Haematologica. 2001;86(8):837-43. [PubMed: 11522540].
  • 21. Kyle RA, Gertz MA, Witzig TE, Lust JA, Lacy MQ, Dispenzieri A, et al. Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc. 2003;78(1):21-33. doi: 10.4065/78.1.21. [PubMed: 12528874].
  • 22. Hu K, Wang J, Zhu MX, Wang YF, Ke XY. [Immunophenotype characteristics of patients with multiple myeloma in different risk stratification]. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2014;22(6):1624-7. doi: 10.7534/j.issn.1009-2137.2014.06.023. [PubMed: 25543486].
  • 23. Guo J, Chang CK, Su JY, Zhang X, Li X. [Recent advances on the prognostic value of immunophenotyping in multiple myeloma by flow cytometry]. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2014;22(4):1178-82. doi: 10.7534/j.issn.1009-2137.2014.04.056. [PubMed: 25130852].
  • 24. Paiva B, Chandia M, Vidriales MB, Colado E, Caballero-Velazquez T, Escalante F, et al. Multiparameter flow cytometry for staging of solitary bone plasmacytoma: new criteria for risk of progression to myeloma. Blood. 2014;124(8):1300-3. doi: 10.1182/blood-2014-04-567909. [PubMed: 24876564].
  • 25. Sahara N, Takeshita A, Shigeno K, Fujisawa S, Takeshita K, Naito K, et al. Clinicopathological and prognostic characteristics of CD56-negative multiple myeloma. Br J Haematol. 2002;117(4):882-5. [PubMed: 12060125].
  • 26. Hundemer M, Klein U, Hose D, Raab MS, Cremer FW, Jauch A, et al. Lack of CD56 expression on myeloma cells is not a marker for poor prognosis in patients treated by high-dose chemotherapy and is associated with translocation t(11;14). Bone Marrow Transplant. 2007;40(11):1033-7. doi: 10.1038/sj.bmt.1705857. [PubMed: 17891186].
  • 27. Rawstron A, Barrans S, Blythe D, Davies F, English A, Pratt G, et al. Distribution of myeloma plasma cells in peripheral blood and bone marrow correlates with CD56 expression. Br J Haematol. 1999;104(1):138-43. doi: 10.1046/j.1365-2141.1999.01134.x. [PubMed: 10027726].
  • 28. Kraj M, Sokolowska U, Kopec-Szlezak J, Poglod R, Kruk B, Wozniak J, et al. Clinicopathological correlates of plasma cell CD56 (NCAM) expression in multiple myeloma. Leuk Lymphoma. 2008;49(2):298-305. doi: 10.1080/10428190701760532. [PubMed: 18231917].
  • 29. Moreau P, Robillard N, Jego G, Pellat C, Le Gouill S, Thoumi S, et al. Lack of CD27 in myeloma delineates different presentation and outcome. Br J Haematol. 2006;132(2):168-70. doi: 10.1111/j.1365-2141.2005.05849.x. [PubMed: 16398651].
  • 30. Guikema JE, Hovenga S, Vellenga E, Conradie JJ, Abdulahad WH, Bekkema R, et al. CD27 is heterogeneously expressed in multiple myeloma: low CD27 expression in patients with high-risk disease. Br J Haematol. 2003;121(1):36-43. doi: 10.1046/j.1365-2141.2003.04260.x. [PubMed: 12670329].
  • 31. Morgan TK, Zhao S, Chang KL, Haddix TL, Domanay E, Cornbleet PJ, et al. Low CD27 expression in plasma cell dyscrasias correlates with high-risk disease: an immunohistochemical analysis. Am J Clin Pathol. 2006;126(4):545-51. doi: 10.1309/ELGMGX81C2UTP55R. [PubMed: 16938662].
  • 32. Moreau P, Robillard N, Avet-Loiseau H, Pineau D, Morineau N, Milpied N, et al. Patients with CD45 negative multiple myeloma receiving high-dose therapy have a shorter survival than those with CD45 positive multiple myeloma. Haematologica. 2004;89(5):547-51. [PubMed: 15136217].
  • 33. Carulli G, Ottaviano V, Cannizzo E, Giuntini S, Manetti C, Ciancia EM, et al. Multiparameter immunophenotyping by flow cytometry as a diagnostic tool in multiple myeloma and monoclonal gammopathy of undetermined significance. Clin Ter. 2012;163(5):387-92. [PubMed: 23099966].
  • 34. Cao FF, Chen F, Hu YP, Zhang JH. [Immunophenotype in multiple myeloma cells detected by multiparameter flow cytometry]. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2012;20(3):620-3. [PubMed: 22739168].
  • 35. Robillard N, Avet-Loiseau H, Garand R, Moreau P, Pineau D, Rapp MJ, et al. CD20 is associated with a small mature plasma cell morphology and t(11;14) in multiple myeloma. Blood. 2003;102(3):1070-1. doi: 10.1182/blood-2002-11-3333. [PubMed: 12702507].
  • 36. Pruneri G, Ponzoni M, Ferreri AJ, Freschi M, Tresoldi M, Baldini L, et al. The prevalence and clinical implications of c-kit expression in plasma cell myeloma. Histopathology. 2006;48(5):529-35. doi: 10.1111/j.1365-2559.2006.02375.x. [PubMed: 16623778].
  • 37. Bataille R, Pellat-Deceunynck C, Robillard N, Avet-Loiseau H, Harousseau JL, Moreau P. CD117 (c-kit) is aberrantly expressed in a subset of MGUS and multiple myeloma with unexpectedly good prognosis. Leuk Res. 2008;32(3):379-82. doi: 10.1016/j.leukres.2007.07.016. [PubMed: 17767956].
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:



Create Citiation Alert
via Google Reader

Readers' Comments